{'52WeekChange': -0.7602682,
 'SandP52WeekChange': 0.0644362,
 'address1': '180 North LaSalle Street',
 'address2': 'Suite 1810',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.86,
 'askSize': 2200,
 'averageDailyVolume10Day': 2342500,
 'averageVolume': 1981255,
 'averageVolume10days': 2342500,
 'beta': 2.035859,
 'beta3Year': None,
 'bid': 2.86,
 'bidSize': 2900,
 'bookValue': 0.721,
 'category': None,
 'circulatingSupply': None,
 'city': 'Chicago',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3,
 'dayLow': 2.75,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.557,
 'enterpriseToRevenue': 16.2,
 'enterpriseValue': 69045784,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.6877143,
 'fiftyTwoWeekHigh': 12.5,
 'fiftyTwoWeekLow': 1.42,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 27273381,
 'forwardEps': -1.78,
 'forwardPE': -1.6067415,
 'fromCurrency': None,
 'fullTimeEmployees': 199,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.025710002,
 'heldPercentInstitutions': 0.58022,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/xerispharma.com',
 'longBusinessSummary': 'Xeris Pharmaceuticals, Inc., a specialty '
                        'pharmaceutical company, develops and commercializes '
                        'ready-to-use injectable and infusible drug '
                        'formulations. Its proprietary XeriSol and XeriJect '
                        'formulation technologies allow for the subcutaneous '
                        'and intramuscular delivery of highly-concentrated, '
                        'ready-to-use formulations of peptides, proteins, '
                        'antibodies, and small molecules using commercially '
                        'available syringes, auto-injectors, multi-dose pens, '
                        "and infusion pumps. The company's lead product "
                        'candidate is Gvoke HypoPen, which has completed Phase '
                        'III clinical trials for the treatment of severe '
                        'hypoglycemia, a potentially life-threatening '
                        'condition in people with diabetes. Its product '
                        'candidates also comprise ready-to-use glucagon that '
                        'is in Phase II clinical trials for the treatment of '
                        'congenital hyperinsulinism, post-bariatric '
                        'hypoglycemia, exercise-induced hypoglycemia in '
                        'diabetes, and hypoglycemia-associated autonomic '
                        'failure, as well as for treating hypoglycemia '
                        'associated with intermittent and chronic conditions, '
                        'and bi-hormonal artificial pancreas closed-loop '
                        'systems. In addition, it develops continuous '
                        'subcutaneous glucagon infusion system of ready-to-use '
                        'glucagon; ready-to-use diazepam formulation, which is '
                        'in Phase I clinical trial for the treatment of acute '
                        'repetitive seizures in patients with epilepsy; and '
                        'Pramlintide-Insulin co-formulation that is in '
                        'pre-clinical stage for treating type 1 and 2 '
                        'diabetes. Xeris Pharmaceuticals, Inc. serves '
                        'patients, caregivers, and health practitioners. The '
                        'company was founded in 2005 and is based in Chicago, '
                        'Illinois.',
 'longName': 'Xeris Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 107526848,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_105901792',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -129487000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.82,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '844-445-5704',
 'previousClose': 2.84,
 'priceHint': 4,
 'priceToBook': 3.9667127,
 'priceToSalesTrailing12Months': 25.2292,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3,
 'regularMarketDayLow': 2.75,
 'regularMarketOpen': 2.82,
 'regularMarketPreviousClose': 2.84,
 'regularMarketPrice': 2.82,
 'regularMarketVolume': 2585667,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 37596800,
 'sharesPercentSharesOut': 0.168,
 'sharesShort': 6315203,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1397794,
 'shortName': 'Xeris Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1707,
 'shortRatio': 3.64,
 'startDate': None,
 'state': 'IL',
 'strikePrice': None,
 'symbol': 'XERS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.557,
 'twoHundredDayAverage': 3.7038848,
 'volume': 2585667,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.xerispharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '60601'}